Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months

Viking Therapeutics' shares recently plunged 42% following investor concerns over a 28% discontinuation rate for its oral obesity drug, VK2735, over 13 weeks. However, the drug demonstrated weight loss comparable to Eli Lilly's oral treatment, with 98% of adverse events reported as mild or moderate, and the company also has an injectable version of VK2735 in Phase 3 trials. This significant market sell-off is presented as an overreaction, potentially creating a buying opportunity given the drug's efficacy profile and broader pipeline, despite initial safety concerns.

Analysis

Viking Therapeutics (VKTX) experienced a severe 42% single-day stock decline following the release of trial data for its oral obesity drug, VK2735. The negative market reaction was primarily driven by a 28% discontinuation rate over 13 weeks, which investors interpreted as a poor safety and tolerability profile, especially when compared to Eli Lilly's competing drug that had a 24% rate over a longer 72-week period. However, this concern is partially mitigated by the trial's high placebo discontinuation rate of 18% and the company's statement that 98% of adverse events were mild or moderate. On the efficacy front, VK2735 demonstrated competitive performance, achieving approximately 12% weight loss after three months. Beyond the oral formulation, Viking's pipeline is supported by an injectable version of VK2735, which is in more advanced Phase 3 trials and previously showed a 15% weight loss in 13 weeks during its Phase 2 study. The situation presents a dichotomy where the market has heavily penalized the stock on tolerability concerns for an earlier-stage oral drug, potentially overshadowing the strong efficacy data and the progress of its lead injectable candidate, which could also be a future acquisition target.

Key Decisions for Investors

• Given the 42% share price collapse, investors with a high risk tolerance may view the current valuation as an attractive entry point, predicated on the view that the market has overreacted to the oral drug's discontinuation rate while undervaluing its efficacy and the more advanced injectable program.
• Investors should closely monitor future catalysts related to the injectable version of VK2735, as any positive news from its Phase 3 trial or plans for monthly dosing could serve as a significant driver for a stock re-rating, independent of the sentiment surrounding the oral formulation.
• It is critical to weigh the drug's demonstrated efficacy and potential for an M&A outcome against the significant risk posed by its tolerability profile, as a high discontinuation rate could present future regulatory and commercial hurdles.